How AI is changing drug development
Machine learning is allowing scientists to speed up the process of drug discovery and development
Drug developers are seeking to speed up the testing and developing of new drugs with the help of artificial intelligence (AI).
Researchers at universities and pharmaceutical giants are testing how AI could drastically cut the length of the discovery and development phase of new treatments, which can typically last "12 years or more", said Vox.
Scientists are using AI to find patterns across "large bodies of disparate data" and produce hypotheses that they "could or would not come up with on their own", said The Economist. These are then tested and used to identify potential new drugs or even "new applications for old drugs".
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
With the technology still in its infancy, the drug data produced by AI is tested and validated before being considered for further development. But experts hope that the next few years of AI research could "materially shift" the way that drugs are developed.
How exactly are scientists using AI?
While generative AI is far away from being able to speed up the clinical testing process of a drug, said Nature, it could potentially help reduce the long period in which the "biological target responsible for a disease" is identified, then "screening for molecules that might interact with it" (the discovery phase) and the subsequent preclinical testing of a drug molecule.
AI can analyse huge swathes of data in days, a task that would take humans years, examining complex protein structures and evaluating potential target molecules.
Being able to sift through billions of data points so quickly means the "potential for new drug discoveries is massive", said Vox. And as machine learning advances, it will only "continue to accelerate the process" of discovering new drugs.
Big Pharma companies are largely spearheading investment in the expansion of AI in drug development, but large tech firms, including Google, and many start-ups, are also cashing in with their own AI tools. Google's AI drug discovery company, Isomorphic Labs, has already signed deals with drug companies worth billions, with promises to "revolutionise the lengthy process", said the Financial Times, and to potentially "halve the time taken to find new medicines", saving companies billions in costs.
What are the implications?
The current system of paying billions to develop drugs, most of which fail in clinical trials, is "unsustainable", Regina Barzilay, professor of AI and Health at the Massachusetts Institute of Technology, told Vox. She added that AI will eventually treat diseases for which there is not yet a drug, and help replace drugs with severe side effects.
The uses of AI "are not all perfect", however, said The Economist. While there is significant indication that deep learning tools will offer greater and greater assistance, AI is far from being able to assist in the entire process of drug creation or remove people entirely from it. There are still questions over its reliability, too, given the critical nature of the field and the weight of decision-making. It is not yet clear when people will be able to "put their full trust" in AI's ability to make critical decisions, said Vox.
What next?
There is little question that AI will have an increasingly deeper involvement in drug development. But the systems need to continually "learn and improve", said Nature, and ultimately, that is a case of having a human to "make and test the molecules they suggest" and feed back the results to the machine. AI still needs to "prove itself fully", said Bloomberg, and the success of its use in drug development will only be ascertained through human studies.
However, more AI-generated drugs will also require new forms of regulation to keep control of development and testing standards. There are signs that these AI drugs are "fast approaching", said The Economist, and "drug regulators will need to up their game to meet the challenge".
The next few years will "demonstrate conclusively" whether AI-developed drugs will prove as successful as some predict, but even "incremental improvements" in drug development "could still be a real boon" for the world.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Richard Windsor is a freelance writer for The Week Digital. He began his journalism career writing about politics and sport while studying at the University of Southampton. He then worked across various football publications before specialising in cycling for almost nine years, covering major races including the Tour de France and interviewing some of the sport’s top riders. He led Cycling Weekly’s digital platforms as editor for seven of those years, helping to transform the publication into the UK’s largest cycling website. He now works as a freelance writer, editor and consultant.
-
What is NASA working on?
In Depth A running list of the space agency's most exciting developments
By Devika Rao, The Week US Published
-
'Presidential debates are more performance art than actual ways to inform'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Musk clears Tesla self-driving hurdle in China
Speed Read The Tesla CEO won China's approval to introduce Full Self-Driving (FSD) cars
By Peter Weber, The Week US Published
-
Immunotherapy and hay fever
The Explainer Research shows that the treatment could provide significant relief from symptoms for many hay fever sufferers
By Richard Windsor, The Week UK Published
-
Lead poisoning remains a threat
The Explainer The toxin is built into our lives
By Devika Rao, The Week US Published
-
How women's pain is often ignored in health care
the explainer The gap in care is especially glaring compared to how men are treated
By Theara Coleman, The Week US Published
-
Doulas are filling the gaps in maternal care for Black women
The Explainer Birth workers are stepping up to support some of the most vulnerable pregnancies
By Theara Coleman, The Week US Published
-
Our microbiome is social like us
The Explainer Microbes can be friendly too
By Devika Rao, The Week US Published
-
How love impacts your health
The Explainer Turns out you actually can die of a broken heart
By Devika Rao, The Week US Published
-
The race to develop male birth control
The Explainer New contraception is being conceived
By Devika Rao, The Week US Published
-
Martha's Rule: patients given right to urgent second opinion
The Explainer Hospitals in England will launch new scheme that will allow access to a rapid treatment review
By Richard Windsor, The Week UK Published